

Voxzogo (vosoritide)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	Initial requests: 6 months Continuation requests: 1 year

Medications	Quantity Limit
Voxzogo (vosoritide)	May be subject to quantity limit

APPROVAL CRITERIA

Initial requests for Voxzogo (vosoritide) may be approved if the following criteria are met:

- I. Individual is less than 18 years of age; **AND**
- II. Individual has a diagnosis of achondroplasia; **AND**
- III. Documentation is provided that diagnosis has been confirmed via genetic mutation in fibroblast growth factor receptor 3 (*FGFR3*); **AND**
- IV. Documentation is provided that individual has epiphyses that have not yet closed.

Continuation requests for Voxzogo (vosoritide) may be approved if the following criteria are met:

- I. There is confirmation of clinically significant improvement in growth velocity; **AND**
- II. Documentation is provided that individual has epiphyses that have not yet closed.

Requests for Voxzogo (vosoritide) may not be approved for the following:

- I. Individual with an eGFR <60 mL/min/1.73 m²; **OR**
- II. Individual using in combination with growth stimulants (growth hormone therapy, insulin-like growth factor 1 or anabolic steroids) (NCT 03197766); **OR**
- III. Individual undergoing limb-lengthening surgery (NCT 03197766); **OR**
- IV. May not be approved when the above criteria are not met and for all other indications.

Key References:

1. BioMarin Pharmaceutical. A Study to Evaluate the Efficacy and Safety of BMN 111 in Children with Achondroplasia. NLM Identifier: NCT 03197766. Last updated: March 2, 2022. Available at: <https://www.clinicaltrials.gov/ct2/show/NCT03197766?term=03197766&draw=2&rank=1>. Accessed: January 17, 2024.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 16, 2024.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
5. Savarirayan R, Tofts L, Irving M, et. al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. *Lancet*. 2020; 396(10252):684-692.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.